Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
The Economic Case for Public Investment in Stem Cell Research
Our analysis shows the measure resulted in over 56,000 jobs created and added approximately $10 billion to the state’s economy.
Posted in -
Early Detection: A New Front in the War on Cancer
Blood tests that find malignancies before they spread couldtransform our approach to treatment, Goldman wrote in Scientific American.
Posted in -
Where Is Big Data When We Need It Most?
Electronic health records — which doctors and hospitals have been collecting for a decade — could powerfully and precisely guide the pandemic response.
Posted in -
COVID-19 Is Normalizing Telehealth and That’s a Good Thing
Stuck at home, people are consulting doctors over the internet rather than in person—an approach to healthcare with many lasting benefits.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
Provider Differences in Biosimilar Uptake in the Filgrastim Market
The speed and extent of biosimilar penetration differ across provider types. Provider awareness and incentives are significantly associated with biosimilar uptake.
Categorized in -
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
-
Health Technology Assessment for the U.S. Healthcare System
A white paper from the USC Schaeffer Center-Aspen Institute Advisory Panel on health technology assessment in the U.S. Experts explore how to better link the price of health technologies to the benefits they provide to patients while ensuring a sustainable healthcare ecosystem that supports innovation.
Categorized in -
The Potential Benefits of Deferred Payment
Hlavka and his colleagues used a hypothetical gene therapy for congestive heart failure to assess the impact of a new payment model on access and outcomes.
Categorized in -
The Association Between Drug Rebates and List Prices
Drug rebates and list prices are positively correlated: On average, a $1 increase in rebates is associated with a $1.17 increase in list price.
Categorized in -
Obesity, Second to Smoking as the Most Preventable Cause of US Deaths, Needs New Approaches
Nearly 40% of Americans are obese, and the numbers are climbing. The U.S. needs to get serious about solutions.
Categorized in